We are pleased to share that we closed a €54M oversubscribed Series B raise to advance our innovative Pulsed Field Ablation technology for treating #atrialfibrillation in the US and EU.
Learn more in our press release: https://t.co/1Xsncm43MO
Excited to share our poster presentation on Coherent Sine Burst Electroporation's first 5 patient case studies and 60-day follow-up at the AF Symposium in Boston.
#AFSymposium2023#Arga#ArgaMedtech
News from #JPM2023!
Raised €10 Mil & achieved first-in-human in just 20 months with our Coherent Sine Burst Electroporation (#CSE) System for atrial fibrillation (#Afib) patients.
➡️ More by @MDDIonline with CEO David Neale: https://t.co/r924lQDF5F
Congrats to our CEO David Neale for being one of the 30 #innovators to watch in 2022 - according to @Dsiliconreview.
🎙Learn more about #Arga in this Q&A with David: https://t.co/gVcbkKtcd2
💡Full list of innovators at: https://t.co/1kuD4WWmd5
#Arga#Medtech#Startups
Thank you @MedTechOutlook for electing us as one of the top 10 #MedTech#startups in #Europe!
Atrial Fibrillation affects 33M + people worldwide, and treatments have a long-term success of 50-70%. Argá's technology addresses this issue.
➡️ More on https://t.co/UfLxklAh8U
We are excited to participate in @lsintelligence#Medtech Summit, an incredible opportunity to connect with other innovators and world-class investors.
📍 Check out our David Neale, CEO & Co-Founder presentation on Sept. 23 at 3 pm BST
#LSIEurope22#MedicalDevices#Cardiology
Atrial fibrillation is the most common irregular #heartbeat type and can lead to stroke or heart failure (@MayoClinic).
@ArgaMedtech developed a #CSE pulsed field ablation catheter, soon to start EU first-in-human #trial, to improve existing treatments🫀
✍️ ⬇️ @Medtech_Insight